Maelstrom Research Staging | VIP_MCAL_360_days_postdose

VIP_MCAL_360_days_postdose_2

Networks -

Variables -

Population

VIP - MCAL patients

The population is composed of patients with myeloid cancers and acute leukemias (MCALs), aged 18 years and older, who intend to receive the COVID-19 vaccine or have received the COVID-19 vaccine at any time in the past.

Selection Criteria

Minimum age

Newborns

Twins

Countries

Canada

Territory

Edmonton, Montreal, Ottawa, Toronto

Ethnic Origin

Health Status

Participants are diagnosed with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or myeloproliferative syndrome (and undergoing cytoreductive therapy).

Participants are excluded if they have chronic myelogenous leukemia, myeloproliferative neoplasm not on cytoreductive therapy, or any absolute contraindications to the COVID-19 vaccine.

Other Criteria

Participants are excluded if they received an autologous stem cell transplantation (autoSCT) or allogeneic hematopoietic stem cell transplantation (alloSCT) treatment for non-hematologic malignancy diseases.

Recruitment

Sources of recruitment

Specific population

Specific Population

Clinic patients

Supplementary Information

Participants are recruited in hematology clinics from one of twelve participating hospitals around Canada.

Number of Participants

Number of Participants: 216
Number of Participants with Biological Samples: 216

More info

Data Collection Event

VIP - MCAL patients - Follow-up 360 days post-dose 2

Information is collected about potential COVID-19 exposures, COVID-19 infections, and changes in medical history. Blood samples are collected.

More info

Collected Dataset / VIP_MCAL_360_days_postdose_2

VIP_MCAL_360_days_postdose_2

Population

VIP - MCAL patients

Data Collection Event

VIP - MCAL patients - Follow-up 360 days post-dose 2

Files

Variables Classifications